Shares of major Indian CRDMO firms including Divi’s Laboratories and Laurus Labs hit all-time highs on Wednesday, supported by a 19% growth in the first quarter of fiscal 2027. While global demand for outsourced drug manufacturing is rising, investors are balancing this rally against risks like uneven revenue and high expansion costs.
Shares of major Indian Contract Research, Development, and Manufacturing Organizations (CRDMO) reached all-time highs during Wednesday's trading session. Investors showed strong confidence in the sector, pushing the stock prices of key players like Divi’s Laboratories and Laurus Labs to record levels. The rally comes after the industry reported a 19% year-on-year growth for the first quarter of fiscal year 2027, marking the strongest performance in seven quarters.
The sector is benefiting from a broader global shift in pharmaceutical supply chains. Many international companies are adopting the 'China+1' strategy, which encourages them to move manufacturing and research activities to alternative locations like India. Additionally, the increasing demand for complex new drugs, such as peptides and Antibody-Drug Conjugates (ADCs), has provided a steady pipeline of work for Indian firms. Companies like Gland Pharma and Sai Life Sciences have also participated in this upward trend, reflecting wider sector interest.
However, investors are also tracking several business challenges that come with this rapid growth. One of the primary risks in the CRDMO business is that revenue can be uneven. Unlike companies with predictable monthly sales, these firms often earn money only when they hit specific project milestones or deliver validation batches. This means that revenue can fluctuate significantly from one quarter to the next, which can sometimes lead to sharp movements in stock prices.
Furthermore, the sector requires high spending on expansion to keep up with global technology standards. Companies are investing heavily in new facilities and specialized labs to handle advanced drug development. While this spending is necessary to win new contracts, it can also put temporary pressure on cash flow and profit margins. Investors should also monitor execution risks, as any delay in setting up these new facilities or completing complex projects on time could impact the company's financial performance.
Looking ahead, the long-term potential of the sector remains tied to its ability to handle increasingly difficult manufacturing tasks. The focus is currently on moving up the value chain toward more complex chemical and biological processes. For shareholders, the most important updates to follow in the coming months will be the progress of these large-scale expansion projects and whether the companies can maintain their profit margins while scaling up their operations.